The association between adiponectin level and non alcoholic fatty liver disease (NAFLD) in obese adolescents
DOI:
https://doi.org/10.36408/mhjcm.v7i2.501Keywords:
NAFLD, adiponectin, HOMA-IR, obesity, adolescentAbstract
Background: Non alcoholic fatty liver disease (NAFLD) has been associated with cytokines and inflammatory mediators. Adiponectin has insulin sensitizing effects and has correlation with severity of NAFLD disease. However, the study about the relationship between adiponectin level and NAFLD is lacking. The objective of the study was to determine the association between adiponectin level and NAFLD in obese adolescents through the role of insulin resistance.
Methods: This was a cross-sectional study, that was done in August 2007. The inclusion criteria were obese adolescents aged 11-14 years, and normal weight adolescent as control group. Adiponectin was assessed by using ELISA, insulin resistance was obtained by Homeostasis Model Assessment Insulin Resistance (HOMA-IR). NAFLD was confirmed by abdominal ultrasound, which represented by fatty liver imaging. The comparison of adiponectin level and HOMA-IR among 3 groups were analyzed by Kruskal Wallis test, meanwhile the correlation between adiponectin level and some variables were analyzed by spearman correlation.
Result: There were 73 subjects, consisted of 37 obese and 36 non obese. Among obese subjects, 54.1% got NAFLD. All of our obese subjects were insulin resistance, the HOMA-IR level of obese non NAFLD was 6.1 and obese with NAFLD was 6.8. The adiponectin levels in normal children was (5.1mg / ml), obese non NAFLD (4.1mg / ml) and obese with NAFLD (4.0 mg / ml) (p <0.001). There were no association between adiponectin level and other variables.
Conclusion: There were significant differences of adiponectin levels and insulin resistance measured by HOMA-IR between normal and obese subjects, but no significant differences between the obese groups with or without NAFLD.
Keywords: NAFLD, adiponectin, HOMA-IR, obesity, adolescent.
Downloads
References
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease BMC Medicine 2017;15:45. Available at https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0806-8
Kim JY, Cho J, Yang HR. Biochemical predictors of early onset non-alcoholic fatty liver disease in young children with obesity. J Korean Med Sci. 2018;33(16):e122. Available from https://pubmed.ncbi.nlm.nih.gov/29651819/
Mexitalia M, Utari A, Sakundarno M, Yamauchi T, Subagio HW, Soemantri A. Sindroma metabolik pada remaja obesitas (Metabolic syndrome at obese adolescences). M Med Indones 2009;43(6):300-5
Prokopowicz Z, Malecka-Tendera E, Matusik P. Predictive value of adiposity level, metabolic syndrome, and insulin resistance for the risk of nonalcoholic fatty liver disease diagnosis in obese children. Can J Gastroenterol Hepatol 2018 Apr 26;2018:9465784. Available at https://www.hindawi.com/journals/cjgh/2018/9465784/
Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 2005; 52: 519-24.
Mathur P, Das MK, Arora NK. Non-alcoholic fatty liver disease and childhood obesity. Indian J Pediatr. 2007; 74: 401-7.
Junior WS, dos Santos JS, Sankarankutty AK, de Castro e Silva O. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras 2006; 21: 72-8.
Anderson EL, Howel LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015 Oct 29;10(10):e0140908. Available at https://pubmed.ncbi.nlm.nih.gov/26512983/
Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int. J. Mol. Sci. 2016, 17, 947; doi:10.3390/ijms17060947. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926480/
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13-5
Br Med J (Clin Res Ed) 1986 ; 292 (6512) :13-5.
Staufer K, Halilbasic E, Spindelboeck W, Eilenberg M, Prager G, Stadlbauer V et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United European Gastroenterol J. 2019; 7(8):1113-23.
Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, et al. Decrease in serum adiponectin level due to obesity and viseral fat accumulation in children. Obes Res 2003; 11: 1072-7.
Winer JC, Zern TL, Taksali SE, Dziura J, Cali AMG, Wollschlager M, et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4415-23.
Ogawa Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Uchiyama M. The usefulness of serum adiponectin level as a diagnostik marker of metabolic syndrome in obese Japanese children. Hypertens Res 2005; 28. 51-7.
Jimenez-Rivera C, Hadjiyannakis S, Davila J, Hurteau J, Aglipay M, Barrowman N, et al. Prevalence and risk factors for nonalcoholic fatty liver in children and youth with obesity. BMC Pediatrics. 2017;17:113. Available at https://pubmed.ncbi.nlm.nih.gov/28446162/
Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115(4): e500-3. Available at https://pediatrics.aappublications.org/content/115/4/e500.long
Jain V, Jana M, Upadhyay B, Ahmad N, Jain O, Upadhyay AD, et al. Prevalence, clinical and biochemical correlates of non-alcoholic fatty liver disease in overweight adolescents. Indian J Med Res 2018;148:291-301
Aksoy GK, Artan R ,Aksoy C, Özdem S, Atalay A, Y?lmaz A. Role of soluble adiponectin receptor 2 in non-alcoholic fatty liver disease in children. Pediatr Gastroenterol Hepatol Nutr. 2019; 22(5):470-8.
Adams LA, Angulo P, Lindor KD. Non alcoholic fatty liver disease. CMAJ 2005; 172(7): 899-905.
Sanyal AJ. Mechanism of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2(1): 46-53.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2020 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
